Mail to a Friend |
|
Rate |
Biofrontera AG has approached U.S.Patent Trial and Appeal Board (PTAB) for its petition to cancel a patent owned by Sun Pharmaceutical Industries Limited?s owned Dusa Pharmaceuticals, Inc. Both the companies have treatments for a pre-cancerous skin condition actinic keratosis. The plaintiff is claiming that the defendant is infringing the patent that covers ?a common off-label use? of the therapy.
User :- TMReady
Email :-rakhi.tushir@sagaciousresearch.com
Url :- https://ipnewsshots.com/biofrontera-appeals-ptab-seeks-cancellation-of-dusas-patent/